ClinVar Miner

Submissions for variant NM_005359.6(SMAD4):c.1476TGA[1] (p.Asp494del)

dbSNP: rs1910518741
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001215527 SCV001387277 uncertain significance Juvenile polyposis syndrome 2023-03-02 criteria provided, single submitter clinical testing This variant, c.1479_1481del, results in the deletion of 1 amino acid(s) of the SMAD4 protein (p.Asp494del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with clinical features of juvenile polyposis syndrome (Invitae). ClinVar contains an entry for this variant (Variation ID: 945003). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002393505 SCV002701127 likely pathogenic Familial thoracic aortic aneurysm and aortic dissection; Hereditary cancer-predisposing syndrome 2017-04-19 criteria provided, single submitter clinical testing The c.1479_1481delTGA variant (also known as p.D494del) is located in coding exon 11 of the SMAD4 gene. This variant results from an in-frame TGA deletion at nucleotide positions 1479 to 1481. This results in the in-frame deletion of an aspartic acid at codon 494. This alteration was detected in an individual with clinical features suggestive of a combined juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome (Ambry internal data). This variant co-segregated with disease in one family tested in our laboratory. Based on internal structural analysis, this alteration destabilizes SMAD4 at its interface with SMAD2/3 (Chacko BM et al. Mol. Cell, 2004 Sep;15:813-23). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by PROVEAN in silico analysis (Choi Y et al., Bioinformatics 2015 Aug; 31(16):2745-7). Based on the majority of available evidence to date, this variant is likely to be pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.